Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB

Key Points

• Corient Private Wealth increased its Biogen stake by 14.7% in the second quarter, adding 5,445 shares to own 42,397 shares valued at approximately $9.16 million. Institutional investors collectively hold 87.93% of Biogen’s stock.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $230.14. Recent targets range from $231 to $300, including upgrades from Wolfe Research and Piper Sandler.
• Biogen reported quarterly EPS of $3.60, beating estimates of $2.94, while revenue reached $2.74 billion versus expectations of $2.46 billion. Shares opened at $216.01, near their 52-week high of $225.80.

Corient Private Wealth LP raised its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 14.7% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 42,397 shares of the biotechnology company's stock after acquiring an additional 5,445 shares during the period. Corient Private Wealth LP's holdings in Biogen were worth $9,160,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Rothschild Investment LLC boosted its holdings in Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 56 shares during the last quarter. Wedbush Securities Inc. boosted its stake in shares of Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock worth $251,000 after buying an additional 56 shares during the last quarter. Meeder Advisory Services Inc. boosted its stake in shares of Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock worth $866,000 after buying an additional 57 shares during the last quarter. Kera Capital Partners Inc. grew its holdings in shares of Biogen by 3.5% in the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 58 shares during the period. Finally, Parallel Advisors LLC increased its position in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company's stock valued at $801,000 after acquiring an additional 65 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Oppenheimer reissued an "outperform" rating and issued a $300.00 target price on shares of Biogen in a research report on Wednesday, July 29th. Wolfe Research upgraded shares of Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a research note on Thursday, August 13th. Piper Sandler reissued an "overweight" rating and issued a $245.00 price objective (up from $225.00) on shares of Biogen in a report on Thursday, September 3rd. Stifel Nicolaus set a $242.00 target price on shares of Biogen in a research report on Thursday, September 10th. Finally, Morgan Stanley upped their target price on shares of Biogen from $222.00 to $231.00 and gave the company an "equal weight" rating in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $230.14.

Biogen Stock Down 0.1%

Shares of BIIB stock opened at $216.01 on Thursday. The company has a market capitalization of $31.92 billion, a price-to-earnings ratio of 38.23, a PEG ratio of 2.39 and a beta of 0.17. Biogen Inc. has a one year low of $135.39 and a one year high of $225.80. The company's fifty day moving average price is $210.27 and its 200-day moving average price is $197.90. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the prior year, the firm posted $5.47 EPS. Biogen's quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts expect that Biogen Inc. will post 12.41 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen's portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.